{"slug":"tirzepatide-glp-1","verification":{"valid":true,"entries":2,"head":"b43a6fce0a59085157031fed3dc715859cf39195e2ce69c2bb410c1b1fbc0a02"},"energy":{"passes":2,"tokens_in":32322,"tokens_out":3231,"tokens_total":35553,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"b43a6fce0a59085157031fed3dc715859cf39195e2ce69c2bb410c1b1fbc0a02"},"provenance":[{"ts":"2026-06-29T22:48:03.697Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tirzepatide for Glp 1\nSlug: tirzepatide-glp-1\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"}],\"drugs_in_scope\":[\"glp1-agonists\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tirzepatide\",\"name\":\"Tirzepatide\",\"section_title\":\"Why Tirzepatide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\",\"**What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\",\"**Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_chains\":[{\"drug\":\"glp1-agonists\",\"name\":\"GLP-1 agonists (class)\",\"section_title\":\"Why GL","response":"{\n  \"slug\": \"tirzepatide-glp-1\",\n  \"title\": \"Tirzepatide for GLP-1 Contexts: Human Trial Data on Weight Loss and Load Reduction\",\n  \"body\": \"## What's breaking down\\n\\nWhen body weight sits higher, mechanical forces on the spine and weight-bearing joints rise. Each extra pound can transmit roughly four times that force through the lumbar spine during everyday movement. Over time this pattern accelerates disc compression, facet joint stress, and cartilage wear. Metabolic factors tied to excess adiposity add inflammatory signals that slow natural repair. The result is a gap where breakdown outpaces regeneration, and symptoms persist even if pain signals are managed short-term.\\n\\n## Why Tirzepatide might help you\\n\\n1. What keeps failing: The same mechanical overload pattern seen in other GLP-1 contexts when body weight remains elevated.\\n2. What Tirzepatide is studied to do: Dual GLP-1/GIP receptor activation that produces substantial weight reduction in adults with obesity or overweight.\\n3. Therefore for you: If the metabolic load layer contributes to your situation, Tirzepatide is discussed because it targets body-weight reduction that lowers compressive forces on the spine and joints, rather than masking symptoms.\\n\\n## Why GLP-1 agonists (class) matters for you\\n\\nGLP-1 agonists as a class support metabolic improvements through weight loss while carrying tradeoffs such as gastrointestinal slowing and potential muscle loss during rapid reduction. The primary documented benefit for load-sensitive readers is mechanical unloading. Each pound lost can reduce knee joint force by approximately three to four pounds during walking. This class-level effect reduces compressive stress rather than suppressing inflammatory signals directly or providing standalone metabolic repair independent of weight change.\\n\\n## How these fit together\\n\\nTirzepatide operates within the GLP-1 agonist framework but adds GIP activity that yields greater average weight loss than semaglutide al","tokens_in":32322,"tokens_out":3231,"cost":0,"prev":"genesis","hash":"45dca31f0af6345c0ff8c90b0d4ca07633bbfb1c8b2f915253092dfaf02fce2b"},{"ts":"2026-07-17T02:43:15.892Z","model":"owner","action":"voxel_divide","prompt":"","input":"tirzepatide-glp-1","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"45dca31f0af6345c0ff8c90b0d4ca07633bbfb1c8b2f915253092dfaf02fce2b","hash":"b43a6fce0a59085157031fed3dc715859cf39195e2ce69c2bb410c1b1fbc0a02"}]}